Clinical Report: ADAM9 as a Crucial Mediator of Efferocytosis in LUAD
Overview
This study identifies ADAM9 as a significant efferocytosis-related gene in lung adenocarcinoma (LUAD), correlating high expression with poor patient survival and immunosuppressive microenvironments. A prognostic model based on ADAM9 and other efferocytosis-related genes was developed, demonstrating predictive accuracy for survival outcomes.
Background
Lung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality, with a low 5-year survival rate for metastatic cases. The identification of molecular biomarkers that reflect tumor-immune interactions is critical for optimizing precision medicine strategies. Efferocytosis, the clearance of apoptotic cells, plays a dual role in tumor progression and immune evasion, highlighting the importance of efferocytosis-related genes (ERGs) like ADAM9.
Data Highlights
Parameter
Value
Number of tumor samples
517
Number of normal samples
59
High-risk group survival correlation
Significant
Key Findings
ADAM9 expression stratified LUAD patients into high- and low-risk groups with significant survival differences.
A nomogram integrating ADAM9 and clinical features showed robust predictive accuracy.
High ADAM9 expression was associated with increased infiltration of M2 macrophages and neutrophils.
Single-cell analysis revealed ADAM9 enrichment in M2 macrophage subsets.
ADAM9 knockdown regulated efferocytosis and M2 macrophage polarization, suppressing tumor cell proliferation via the IL-6/STAT3 pathway.
Clinical Implications
The findings suggest that ADAM9 could serve as a potential prognostic and therapeutic target in LUAD, particularly in developing strategies to modulate the tumor microenvironment. Clinicians may consider integrating ADAM9 expression levels into patient assessments to better predict outcomes and tailor therapies.
Conclusion
This study underscores the oncogenic role of ADAM9 in LUAD and its potential as a biomarker for predicting patient survival and therapeutic responses. Further research is warranted to explore ADAM9-targeted therapies in clinical settings.
